title: Synthesis, molecular targets, and antitumor activities of substituted tetrahydro-1-oxopyrano[4,3-b][1]benzopyrans and nanogels for drug delivery.
abstract: A class of substituted 1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-b][1]benzopyrans (tricyclic pyrones; TPs) was synthesized from a one-pot condensation reaction of 6-substituted 4-hydroxy-2-pyrones and cyclohexenecarboxaldehydes. The reaction involves a 6pi-electrocyclic ring closing process, and stereo- and regioselectivities were examined. C3-Pyridyl-containing TPs may represent a novel synthetic class of microtubule de-stabilizing anti-cancer drugs that inhibit macromolecule synthesis, tubulin polymerization, and the proliferation of a spectrum of wild-type and multi-drug resistant tumor cell lines in vitro. A linear skeleton with a N-containing aromatic ring attached at C3 of the top A-ring, a central pyran B-ring and a six-membered bottom C-ring with no alkylation at C7 are required for the antitumor activities of the lead compounds, a 3-pyridyl benzopyran (code name H10) and its 2-pyridyl regioisomer (code name H19). In addition to interacting with the colchicine-binding site to inhibit tubulin polymerization and increase the mitotic index, these TP analogs also block the cellular transport of nucleosides to inhibit DNA synthesis more effectively than other antimitotic agents. The anticancer potential of TPs in vivo is suggested by the fact that i.p. injections of H10 decrease the growth of solid tumors in mice inoculated with lung or ovarian carcinomas. A drug-delivery system involving nanogels was studied. We incorporated the anticancer compound, 6-hydroxymethyl-1,4-anthracenedione (code name AQ10) into PEG-PEI nanogel, and found that AQ10-encapsulated nanogel PEG-PEI is significantly more effective in altering the growth of Pan 02 (pancreatic cancer) cells compared to AQ10 or nanogel PEG-PEI alone. Since AQ10 is insoluble in water, PEG-PEI encapsulation represents a way to solubilize and deliver this as well as other poorly soluble compounds.
authors.affiliation: Anti-Cancer Drug Laboratory, Division of Biology, Kansas State University, Manhattan, KS 66506-4901, USA.
authors.forename: Elisabeth M
authors.initials: EM
authors.lastname: Perchellet
authors.forename: Jean-Pierre H
authors.initials: JP
authors.lastname: Perchellet
authors.forename: Chanran K
authors.initials: CK
authors.lastname: Ganta
authors.forename: Deryl L
authors.initials: DL
authors.lastname: Troyer
authors.forename: Aibin
authors.initials: A
authors.lastname: Shi
authors.forename: Duy H
authors.initials: DH
authors.lastname: Hua
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology*; D001578:Benzopyrans / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology*; D004337:Drug Carriers; D004354:Drug Screening Assays, Antitumor; D049329:Nanostructures
chemical_list: D000970:Antineoplastic Agents; D001578:Benzopyrans; D004337:Drug Carriers